Definitive Contract 75N93022C00059
Award Date 9/20/22
Potential Completion Date 9/30/26
Potential Value $18M
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Menlo Park, CA 94025, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
30
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, awarded a $15,505,000.31 definitive cost-no-fee contract to Entasis Therapeutics Inc., a subsidiary of Innoviva, Inc., to identify and develop a non-beta-lactam penicillin-binding protein (PBP) inhibitor with broad-spectrum activity against multidrug-resistant Gram-negative ESKAPE pathogens. This work directly responds to a NIAID solicitation for proposals addressing...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a definitive contract to Revagenix Inc. valued at approximately $27.8 million on September 22, 2022, for the development of a novel LPXC inhibitor with pan-resistant Pseudomonas and Burkholderia activity. The contract, which will be performed in San Mateo, California, is structured as a cost-plus-fixed-fee arrangement with an ultimate completion date of April 25, 2028. This award originated from a Broad Agency Announcement...
- This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...
- The Office of the Assistant Secretary for Preparedness and Response awarded a $267.6 million definitive contract to Basilea Pharmaceutica International Ltd for the development of antimicrobials to treat resistant fungal and bacterial infections on September 30, 2024, under a cost-sharing pricing model with no set-aside. Place of performance is Switzerland. The contract executes CLIN 0003 under an OTA solicitation and extends through December 31, 2035. The originating BAA, posted in October 2017,...
- The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, has awarded a $164,300,757.00 definitive cost-sharing contract to Melinta Therapeutics, LLC, a for-profit limited liability company and manufacturer of pharmaceutical products. The purpose of this contract is to advance the development of two antibiotics for use in the pediatric population to treat serious bacterial infections where multidrug-resistant organisms are common, as...
- This is a $7,621,277 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Microbiotix, Inc., a clinical-stage biopharmaceutical company in Worcester, Massachusetts. The contract is to develop phenoxyacetamide T3SS inhibitors as adjunctive agents to antibacterial therapy for treating multidrug-resistant Pseudomonas aeruginosa infections. This work was originally solicited through a Broad Agency Announcement seeking proposals to develop...
- The U.S. Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response (ASPR), awarded a $481.7 million cost-plus-fixed-fee definitive contract to Shionogi Inc. on April 6, 2026, for late-stage development, FDA marketing authorization, procurement, and stockpiling of antibiotics to treat drug-resistant secondary bacterial infections and infections caused by biothreat pathogens. The contract, which extends through March 10, 2036, supports ASPR's...
- <p>The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $28.2 million definitive contract to Venatorx Pharmaceuticals Inc. for development of therapeutic medical countermeasures for biodefense and emerging infectious diseases on September 16, 2013, under cost-plus-fixed-fee pricing with no set-aside.</p> <p>Place of performance is Malvern, Pennsylvania. The contract ceiling is $28,199,895.53 with an ultimate completion date of September 30, 2019.</p>
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $28.99 million cost-plus-fixed-fee definitive contract to Resilience Government Services, Inc. (doing business as Nanotherapeutics Inc.) on September 9, 2019, with completion targeted for August 17, 2024. The contract supports the production of monoclonal antibody (MAB)-based therapeutics directed against botulinum neurotoxin serotype F subtypes, encompassing work across the diverse spectrum of highly variable...
- This is a federal contract award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Emory University. The $3,458,502.19 cost-no-fee contract is for "TARGETING THERAPEUTICS DEVELOPMENT TO RELIEVE BOTTLENECKS: OPTIMIZONG LEAD THERAPEUTIC COMPOUNDS AGAINST INFECTIOUS PATHOGENS." It has a period of performance through October 31, 2018. The contract is not designated as a set-aside. The contract has several...